
Loading, please wait...

Loading, please wait...

Q1: Why do some breast cancer patients stop responding to hormone therapy?
Research indicates that the loss of the CDKN1B gene prevents the production of the p27 protein. Without this protein, cancer cells can bypass the inhibitory effects of standard hormone drugs, leading to resistance.
Q2: How can doctors identify patients at risk of treatment failure?
Pathologists can check p27 levels using routine diagnostic tests on tumor samples. Low or absent p27 levels signal a high risk of developing resistance to standard hormone treatments.
Q3: What are the treatment options if this genetic defect is found?
Doctors may initiate stronger combination therapies earlier in the treatment plan. Identifying the defect early allows for more aggressive or targeted approaches to prevent a relapse.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Indian researchers identify CDKN1B gene loss as a key driver of hormone resistance in HR+ breast cancer, suggesting p27 as a biomarker for precise treatment...
4 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today